Additive Effects of Pravastatin and Valsartan

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01004237

Enrollment

Registered

2009-10-29

Start date

2009-11-30

Completion date

2012-04-30

Last updated

2012-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Cholesterol, Hypertension

Keywords

insulin resistance, hypertensive, hypercholesterolemic patients

Brief summary

The investigators hypothesize that pravastatin combined with valsartan may have additive effects in hypertensive, hypercholesterolemic patients.

Interventions

DRUGpravastatin, valsartan, pravastatin+valsartan

pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

25 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Hypertension and low-density lipoprotein cholesterol levels \>100

Exclusion criteria

* Overt liver disease Chronic renal failure Hypothyroidism Myopathy Uncontrolled diabetes Severe hypertension

Design outcomes

Primary

Measure	Time frame
flow-mediated dilation	8 weeks of treatment

Secondary

Measure	Time frame
insulin resistance	8 weeks of treatment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026